Drug companies aren’t making new antibiotics. Is there an economic cure?
As drug-resistant infections proliferate, financial barriers are preventing the pharmaceutical industry from investing in new drugs to fight off superbugs. Economics correspondent Paul Solman, in a series of reports with science correspondent Miles O'Brien, explores how researchers could be incentivized to develop new antibiotics.
▶︎
Antibiotic Resistance: How Humans Ruined Miracle Drugs
▶︎
Could soil from an ancient grave help solve the antibiotics crisis?
▶︎
When Antibiotics Don't Work (full documentary) | FRONTLINE
▶︎
The asbestos problem is worse than we thought
▶︎
The accident that changed the world - Allison Ramsey and Mary Staicu
▶︎
This Is What Brexit Cost the World
▶︎
The Human Cell Is Wildly Complex. Can AI Decode It? | Silvana Konermann | TED
▶︎
LAWYER: When Police Say "Safety Check" — Say THESE 5 Words
▶︎
‘VOID OF REALITY LIE’: Trump keeps pushing reflecting pool ‘vandals’ conspiracy
▶︎
Teens unable to walk, mothers with rash-covered babies: How Kush is ruining lives
▶︎
The drugs don't work: a global antibiotics crisis | FT Investigation
▶︎
Why the U.K. Can’t Keep a Prime Minister | WSJ
▶︎
The Virus That Kills Drug-Resistant Superbugs
▶︎
Understanding the shift from plant-based to synthetic drugs
▶︎
What causes antibiotic resistance? - Kevin Wu
▶︎
7 Things Most Seniors Do That Are Secretly Wrecking Their Health
▶︎
The financial barrier to developing antibiotics? No big payday for drug companies
▶︎
How we're using AI to discover new antibiotics | Jim Collins
▶︎
Doctors Explain Why U.S. Healthcare Is So Expensive (HBO)
▶︎